Certior Financial Group LLC Invests $228,000 in Sanofi (NASDAQ:SNY)

Certior Financial Group LLC bought a new stake in Sanofi (NASDAQ:SNY) during the fourth quarter, Holdings Channel reports. The fund bought 4,729 shares of the company’s stock, valued at approximately $228,000.

A number of other institutional investors have also modified their holdings of SNY. Rahlfs Capital LLC acquired a new position in Sanofi in the 4th quarter worth $336,000. Grantham Mayo Van Otterloo & Co. LLC acquired a new position in Sanofi during the 4th quarter valued at approximately $906,000. World Investment Advisors grew its position in shares of Sanofi by 4.4% during the fourth quarter. World Investment Advisors now owns 50,544 shares of the company’s stock worth $2,438,000 after acquiring an additional 2,114 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Sanofi by 4.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 155,078 shares of the company’s stock valued at $7,479,000 after buying an additional 7,123 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Sanofi by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 257,655 shares of the company’s stock worth $12,427,000 after purchasing an additional 2,917 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on SNY shares. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 target price for the company. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Stock Down 4.8 %

NASDAQ:SNY opened at $51.98 on Monday. The stock’s fifty day moving average price is $55.37 and its two-hundred day moving average price is $52.65. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company has a market cap of $131.92 billion, a price-to-earnings ratio of 20.88, a P/E/G ratio of 1.01 and a beta of 0.57. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, analysts anticipate that Sanofi will post 4.36 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.